Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Discogen for lænderygsmerter

29. september 2026 opdateret af: Clark Smith, Columbia University

Dobbeltblindet pilotgennemførlighedsundersøgelse af Discogen-anordningen til at lindre diskogene ryg-/radikulære bensmerter

This study will be a double-blinded, two-arm, prospective, randomized controlled pilot feasibility study in 40 evaluable subjects (20 in each arm) at one study site within the United States. Subjects in Arm 1 will receive unilateral Discogen treatment; subjects in Arm 2 will receive unilateral sham treatment (control). Treatment in both arms can include medications, e.g. NSAIDs or muscle relaxants for axial or radicular pain.

Studieoversigt

Detaljeret beskrivelse

This study will be a double-blinded, two-arm, prospective, randomized controlled pilot feasibility study in 40 evaluable subjects (20 in each arm) at one study site within the United States. Subjects in Arm 1 will receive unilateral Discogen treatment; subjects in Arm 2 will receive unilateral sham treatment (control). Treatment in both arms can include medications, e.g. NSAIDs or muscle relaxants for axial or radicular pain. This study will enroll 40 evaluable subjects and follow them for 60 days.

  1. Investigate the safety and feasibility of the Discogen device to alleviate back/radicular leg pain

  2. Assess the mean reduction in back and radicular leg pain following Discogen treatment.

    • Primary Safety - collection of all adverse events, including any device- or procedure-related adverse events

    • Primary Effectiveness -percent change from baseline for Numerical Pain Scale (NPS) radicular leg pain at 30 and 60 days. The scale ranges from 0(No pain) to 10 (Severe pain).

    • Secondary Effectiveness:

      • Change from baseline in Oswestry Disability Index at 30 and 60 days. The Index ranges from 0-20% (minimal disability), 21-40% (moderate disability), 41-60% (severe disability), 61-80% (crippled), to 81-100% (bed bound).
      • Percent change from baseline NPS back pain at 30 and 60 days

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

5

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Columbia University Irving Medical Center
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

The subject may be included in the study if the following conditions are met:

  1. Adult (> 21 y.o.) males and females legally able and willing to participate and provide consent in the study and attend follow-up visits
  2. Able and willing to complete study forms and communicate with the investigator
  3. Presenting with unilateral radicular leg pain with or without axial back pain of >1 month duration
  4. No epidural injections at treatment site within the last three months
  5. Leg NPS pain score of 4 - 9 in the last month (on a scale of 0 to 10)
  6. Clinical presentation of sensory radiculopathy referable to single-level disc disease/herniation at L3-4, L4-5 or L5-S1
  7. MRI lumbar spine negative for extruded disc herniation, tumor, or bleeding, but positive for disc disease/herniation at L3-4, L4-5 or L5-S1 with mild to moderate foraminal or spinal stenosis (less than 50%).

Exclusion Criteria:

  1. Pregnant or breastfeeding patient
  2. Younger than 21 or older than 75 years
  3. Presenting with motor deficits
  4. Presenting with a baseline Oswestry Disability Index ≥ 41% (severe disability or worse)
  5. Presence of metal hardware within the lumbosacral spine
  6. History of spine surgery at the level of treatment.
  7. Lumbar spine pathology that may increase procedural risk and/or influence symptoms and/or generate unrelated adverse events (per the discretion of the study PI)
  8. Severe lumbar central canal stenosis (greater than 50%)
  9. Severe lumbar foraminal stenosis (greater than 50%)
  10. Severe herniated lumbar disc 4(Grade 2 and above)
  11. Lumbar instability on flexion/extension plain films, greater the Grade 1 spondylolisthesis
  12. Unable to understand and complete research questionnaires
  13. Any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcomes.
  14. BMI greater than 30
  15. Implanted spinal stimulators
  16. Epidural injections at treatment site within the last three months

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment Group

Study subjects in the treatment group (Arm 1) will receive 3 daily Discogen treatments unilaterally within a one week (M-M) period, each lasting 25 minutes.

The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.

The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.

The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge

Sham-komparator: Sham Control Group

Subjects in the sham control arm (Arm 2) will receive 3 daily non-powered treatments unilaterally within a one week (M-M) period, each lasting 25 minutes

The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary Effectiveness
Tidsramme: 30 and 60 days.

Percent change from baseline for Numerical Pain Scale (NPS) radicular leg pain at 30 and 60 days. The NPS is a patient-reported assessment of pain intensity, ranging from 0 (No pain) to 10 (Severe pain).

30 and 60 days.
Primary Safety
Tidsramme: 60 days

Collection of all adverse events, including any device or procedure-related adverse events.

60 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in Oswestry Disability Index
Tidsramme: 30 and 60 days.

The Oswestry Disability Index is a patient-reported assessment of level of function (disability) in those living with low back pain. The Index ranges from 0-20% (minimal disability), 21-40% (moderate disability), 41-60% (severe disability), 61-80% (crippled), to 81-100% (bed bound).

30 and 60 days.
Numerical Pain Scale (NPS)
Tidsramme: 30 and 60 days.

Percent change from baseline NPS back pain. The scale ranges from 0 (No pain) to 10 (Severe pain).

30 and 60 days.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Clark Smith, MD, PhD, Columbia University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. marts 2025

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

30. august 2027

Datoer for studieregistrering

Først indsendt

23. september 2024

Først indsendt, der opfyldte QC-kriterier

23. september 2024

Først opslået (Faktiske)

25. september 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner